dr. camidge on optimal therapy in egfr nsclc
Published 5 years ago • 226 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:58
dr. camidge on mechanisms of resistance to tkis in nsclc
-
1:55
dr. d. ross camidge on targeted therapies in adjuvant non-small cell lung cancer
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:28
dr. camidge on met as a target in lung cancer
-
9:36
dr. d ross camidge on teliso-v monotherapy in patients with previously treated c-met advanced nsclc
-
0:58
dr. camidge on inhibiting initial activating egfr mutations and the t790m resistance mutation
-
1:27
dr. camidge on the keynote-024 trial in nsclc
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
4:59
egfr therapy in nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
5:10
sequencing egfr-targeted therapies in nsclc
-
9:39
emerging therapies in egfr-positive nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
8:00
strategies for approaching frontline therapy in egfr nsclc
-
1:15
dr. aggarwal on triplet therapy in egfr-mutant lung cancer
-
5:00
options for up-front therapy in egfr-mutant nsclc